Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, forecasts substantial growth for China's colorectal cancer drug market. The new Emerging Markets -- China report entitled Colorectal Cancer in China finds that a rapidly aging population will be a key driving force behind the almost 20% increase in the colorectal cancer diagnosed incident population between 2006 and 2011 in China, as the average life expectancy rises and deaths from infectious disease fall.

"Sustained migration from rural to urban China during the past decades exposes more individuals to risk factors for colorectal cancer, such as Western nutritional patterns and sedentary lifestyles," said Victor Li, analyst at Decision Resources. "The burden of disease will grow disproportionately in cities as a result of urbanization."

The report also finds that Sanofi-Aventis's Eloxatin and Jiangsu LYG Hengrui's Ai Heng will continue to dominate the market, but that sales of Roche's Xeloda and biologics such as Merck's Erbitux and Roche's Avastin will grow most rapidly during the next five years.

About Emerging Markets -- China

Emerging Markets -- China is the first and only syndicated report series focusing on high-growth emerging markets with comprehensive disease-specific analysis. With these reports, biopharmaceutical companies can:

      -- More accurately assess the commercial opportunity for Western          brands in key pharmaceutical markets of China -- Beijing, Shanghai,          Guangzhou -- and in the high-growth second-tier markets of Tianjin,          Wuhan, Nanjing, Hangzhou, and Jinan.       -- Understand the physician treatment patterns and drivers of choice          in key first- and second-tier cities based on primary research.       -- Gain a clear perspective of the Chinese five-year market forecast          at the drug level, broken out by urban and rural areas, and by          sales from multinational and Chinese-based companies.    About Decision Resources 

Decision Resources, Inc., ( is a world leader in healthcare market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:   Elizabeth Marshall   Decision Resources, Inc.   781-296-2563 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,

Employers Move to Self-Insured Health Plans Opting to Bear the Financial Risk Themselves

View Now